filmov
tv
Treatment for cancer patients with autoimmune disease | OSUCCC – James
Показать описание
Immunotherapy has revolutionized cancer care, but there can be side effects with the breakthrough treatments. Fortunately for patients, multidisciplinary care can alleviate some of the unwelcome symptoms that can arise from this relatively new class of therapies.
Immunotherapy drugs treat cancer by helping to activate patients’ immune systems to better detect and kill the cancerous cells growing and hiding in their bodies.
However, about “30 to 40 percent of the patients [treated with immunotherapy drugs] develop an autoimmune disease, and that’s where I come in,” says Alexa Meara, MD, a rheumatologist who specializes in treating autoimmune diseases. “It can happen at any point in the treatment, although it’s most common in the first three to six months. It can even happen a year after a patient is off these drugs.”
Patients who receive immunotherapy can develop a number of autoimmune diseases, including rheumatoid arthritis and vasculitis, which can greatly affect their quality of life.
“Every patient is different,” Meara says, adding that symptoms can be minor (a rash or dry eyes) or more serious (inflammation and joint pain).
Meara and her colleagues are addressing these types of issues by through pioneering studies and clinical trials aimed at reducing symptoms.
“This is a really exciting field because it’s so new and it’s so collaborative,” says Meara, who works closely with Ohio State oncologists to treat cancer patients who develop autoimmune symptoms. She is also part of an international consortium that shares ideas and results.
“Helping patients bring back that joy for life” is what motivates Meara. “I’m here for our patients, and at the end of the day, I treat them how I’d want to be treated.”
Learn more about cancer care and research at The Ohio State University:
Follow The James on social media:
Immunotherapy drugs treat cancer by helping to activate patients’ immune systems to better detect and kill the cancerous cells growing and hiding in their bodies.
However, about “30 to 40 percent of the patients [treated with immunotherapy drugs] develop an autoimmune disease, and that’s where I come in,” says Alexa Meara, MD, a rheumatologist who specializes in treating autoimmune diseases. “It can happen at any point in the treatment, although it’s most common in the first three to six months. It can even happen a year after a patient is off these drugs.”
Patients who receive immunotherapy can develop a number of autoimmune diseases, including rheumatoid arthritis and vasculitis, which can greatly affect their quality of life.
“Every patient is different,” Meara says, adding that symptoms can be minor (a rash or dry eyes) or more serious (inflammation and joint pain).
Meara and her colleagues are addressing these types of issues by through pioneering studies and clinical trials aimed at reducing symptoms.
“This is a really exciting field because it’s so new and it’s so collaborative,” says Meara, who works closely with Ohio State oncologists to treat cancer patients who develop autoimmune symptoms. She is also part of an international consortium that shares ideas and results.
“Helping patients bring back that joy for life” is what motivates Meara. “I’m here for our patients, and at the end of the day, I treat them how I’d want to be treated.”
Learn more about cancer care and research at The Ohio State University:
Follow The James on social media:
Комментарии